Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | Director | January 02, 2024 | January 03, 2024 |
| NOVELION THERAPEUTICS INC.NVLN · Entity 152369 | Director | January 27, 2017 | February 03, 2017 |
| PALISADE BIO, INC.CUR · Entity 5803 | Director | July 01, 2019 | July 03, 2019 |
| SEELOS THERAPEUTICS, INC.APRI · Entity 93662 | Director | January 04, 2018 | January 08, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date January 02, 2024 · Filed January 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,801 |
Reported balance
After 2024-01-02 transaction · row 1
1 source rowRow 1 · 2024-01-02 · Grant · Acquired 148 · Balance 18,801 F1: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $84.12, representing the Issuer's closing stock price on January 2, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $84.12, representing the Issuer's closing stock price on January 2, 2024.
NOVELION THERAPEUTICS INC.
Report date January 27, 2017 · Filed February 03, 2017 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 1,048 |
Reported balance
After 2017-01-27 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2017-01-27 · Exercise / conversion · Acquired 456 · Balance 1,048 F1: Reflects a one-for-five share consolidation of the common shares of Novelion Therapeutics Inc. effective December 16, 2016. F2: Each restricted stock unit represents a contingent right to receive one common share. F3: This Form 4/A is being filed to correct an inaccuracy in the Form 4 filed on January 31, 2017, which indicated that 148 common shares deliverable upon vesting of restricted stock units held by the Reporting Person were withheld to cover taxes payable by the Reporting Person. No shares were withheld. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a one-for-five share consolidation of the common shares of Novelion Therapeutics Inc. effective December 16, 2016.
F2: Each restricted stock unit represents a contingent right to receive one common share.
F3: This Form 4/A is being filed to correct an inaccuracy in the Form 4 filed on January 31, 2017, which indicated that 148 common shares deliverable upon vesting of restricted stock units held by the Reporting Person were withheld to cover taxes payable by the Reporting Person. No shares were withheld.
PALISADE BIO, INC.
Report date July 01, 2019 · Filed July 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 219,916 |
Reported balance
After 2019-07-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-07-01 · Grant · Acquired 166,667 · Balance 219,916 F1: The shares represented are restricted stock grants pursuant to 50% of compensatory Annual Grant for director services equal to $50,0000. The shares vest quarterly on 9/30/19, 12/31/19, 3/31/20, and 6/30/2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares represented are restricted stock grants pursuant to 50% of compensatory Annual Grant for director services equal to $50,0000. The shares vest quarterly on 9/30/19, 12/31/19, 3/31/20, and 6/30/2020.
SEELOS THERAPEUTICS, INC.
Report date January 04, 2018 · Filed January 08, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.11 · Expires 2028-01-04 | Direct | 35,000 |
Reported balance
After 2018-01-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-04 · Grant · Acquired 35,000 · Balance 35,000 F1: The options to purchase shares of common stock were issued to the Reporting Person, a non-employee director of Issuer, as an annual stock option grant for his service as a director of the Issuer. F2: The options shall vest with respect to 1/12th of the underlying shares monthly, commencing with the first monthly vesting date of February 4, 2018, so that such options are fully vested on January 4, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The options to purchase shares of common stock were issued to the Reporting Person, a non-employee director of Issuer, as an annual stock option grant for his service as a director of the Issuer.
F2: The options shall vest with respect to 1/12th of the underlying shares monthly, commencing with the first monthly vesting date of February 4, 2018, so that such options are fully vested on January 4, 2019.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AKCEA THERAPEUTICS, INC.
Report date October 12, 2020 · Filed October 13, 2020
Section 16 reporting ended · disclosed 2020-10-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.21 · Expires 2027-06-04 | Direct | 0 |
Reported balance
After 2020-10-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-10-12 · Disposition to issuer · Disposed 52,837 · Balance 0 F1: This option, which provided that 25% of the shares would vest in equal yearly installments over four years on the anniversary of March 13, 2017, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $313,851.78, representing the difference between the exercise price of the option and the acquisition price of $18.15. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.14 · Expires 2030-04-12 | Direct | 0 |
Reported balance
After 2020-10-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-12 · Disposition to issuer · Disposed 26,400 · Balance 0 F2: This option, which provided for vesting of the shares on April 13, 2021, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $53,064.00, representing the difference between the exercise price of the option and the acquisition price of $18.15. |
Filing footnotes · ownership attribution and instrument terms
F1: This option, which provided that 25% of the shares would vest in equal yearly installments over four years on the anniversary of March 13, 2017, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $313,851.78, representing the difference between the exercise price of the option and the acquisition price of $18.15.
F2: This option, which provided for vesting of the shares on April 13, 2021, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $53,064.00, representing the difference between the exercise price of the option and the acquisition price of $18.15.
Aegerion Pharmaceuticals, Inc.
Report date November 29, 2016 · Filed November 30, 2016
Section 16 reporting ended · disclosed 2016-11-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 1
1 source rowRow 1 · 2016-11-29 · Disposition to issuer · Disposed 2,890 · Balance 0 F1: Disposed of in exchange for 2,963 common shares of Novelion Therapeutics Inc. ("Novelion") pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective November 29, 2016. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc." |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.28 · Expires 2022-01-03 | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-11-29 · Disposition to issuer · Disposed 16,435 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 (the "Exchange Ratio") by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2022-06-05 | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-11-29 · Disposition to issuer · Disposed 8,569 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 (the "Exchange Ratio") by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.73 · Expires 2023-06-26 | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-11-29 · Disposition to issuer · Disposed 14,700 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 (the "Exchange Ratio") by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.55 · Expires 2024-06-26 | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2016-11-29 · Disposition to issuer · Disposed 5,012 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 (the "Exchange Ratio") by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.98 · Expires 2025-06-26 | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2016-11-29 · Disposition to issuer · Disposed 18,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 (the "Exchange Ratio") by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.26 · Expires 2025-08-20 | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2016-11-29 · Disposition to issuer · Disposed 40,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 (the "Exchange Ratio") by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2016-11-29 · Disposition to issuer · Disposed 8,888 · Balance 0 F3: Each restricted stock unit represented a contingent right to receive one share of common stock. F5: Pursuant to the Merger Agreement, each restricted stock unit with respect to common stock of the Issuer ("Aegerion RSU") that was outstanding as of immediately prior to the effective time of the merger was exchanged for a restricted stock unit ("Novelion RSU") with respect to a number of common shares of Novelion equal to the product obtained by multiplying (i) the total number of shares of common stock of the Issuer subject to the Aegerion RSU immediately prior to the effective time of the merger by (ii) the Exchange Ratio. Each Novelion RSU is subject to the same terms and conditions applicable to the corresponding Aegerion RSU and the agreements evidencing grant of the Aegerion RSUs thereunder, including vesting terms, but excluding any terms that are rendered inoperative solely by reason of the merger. F4: 16.67% of the grant vested on January 27, 2016 and an additional 16.67% vested on July 27, 2016. Subject to the Reporting Person continuing to serve as a member of the board of the Issuer, an additional 16.67% of the grant was to vest on each of January 27, 2017, July 27, 2017, January 27, 2018 and August 21, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of in exchange for 2,963 common shares of Novelion Therapeutics Inc. ("Novelion") pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective November 29, 2016. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc."
F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 (the "Exchange Ratio") by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor.
F3: Each restricted stock unit represented a contingent right to receive one share of common stock.
F4: 16.67% of the grant vested on January 27, 2016 and an additional 16.67% vested on July 27, 2016. Subject to the Reporting Person continuing to serve as a member of the board of the Issuer, an additional 16.67% of the grant was to vest on each of January 27, 2017, July 27, 2017, January 27, 2018 and August 21, 2018.
F5: Pursuant to the Merger Agreement, each restricted stock unit with respect to common stock of the Issuer ("Aegerion RSU") that was outstanding as of immediately prior to the effective time of the merger was exchanged for a restricted stock unit ("Novelion RSU") with respect to a number of common shares of Novelion equal to the product obtained by multiplying (i) the total number of shares of common stock of the Issuer subject to the Aegerion RSU immediately prior to the effective time of the merger by (ii) the Exchange Ratio. Each Novelion RSU is subject to the same terms and conditions applicable to the corresponding Aegerion RSU and the agreements evidencing grant of the Aegerion RSUs thereunder, including vesting terms, but excluding any terms that are rendered inoperative solely by reason of the merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2024 Filed Jan 3, 2024 21:25 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 148 | $84.12 | $12,449.76 |
DisclosureSEC source: 0001127602-24-000429 · form4.xml · nonDerivative · entry 1 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,801 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $84.12, representing the Issuer's closing stock price on January 2, 2024. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 20:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 448 | $27.88 | $12,490.24 |
DisclosureSEC source: 0001127602-23-025174 · form4.xml · nonDerivative · entry 1 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,653 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $27.88, representing the Issuer's closing stock price on October 2, 2023. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 20:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 374 | $33.36 | $12,476.64 |
DisclosureSEC source: 0001127602-23-020059 · form4.xml · nonDerivative · entry 1 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,205 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $33.36, representing the Issuer's closing stock price on July 3, 2023. Read SEC document |
| May 10, 2023 Filed May 18, 2023 21:18 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $37.89 | $0.00 |
DisclosureSEC source: 0001127602-23-016208 · form4.xml · derivative · entry 2 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-05-10 F2 · kind: Options shall vest and become exercisable in 12 equal monthly installments, the first such installment vesting on 06/10/2023 and the last such installment vesting on 05/10/2024. Read SEC document |
| May 10, 2023 Filed May 18, 2023 21:18 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-016208 · form4.xml · nonDerivative · entry 1 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,831 F1 · kind: Comprised of restricted stock units that will vest in full and in one installment on 05/10/2024. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 20:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 298 | $37.71 | $11,237.58 |
DisclosureSEC source: 0001127602-23-012545 · form4.xml · nonDerivative · entry 1 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,831 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of director's annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $37.71, representing the closing stock price of the Issuer's common stock on April 3, 2023. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 23:36 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 253 | $44.35 | $11,220.55 |
DisclosureSEC source: 0001127602-23-000707 · form4.xml · nonDerivative · entry 1 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,533 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in leu of cash for all or part of directors' annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $44.35, representing the closing stock price of the Issuer's common stock on January 3, 2023. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 110 | $51.11 | $5,622.10 |
DisclosureSEC source: 0001127602-22-023700 · form4.xml · nonDerivative · entry 1 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,280 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in leu of cash for all or part of directors' annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $51.11, representing the closing stock price of the Issuer's common stock on October 3, 2022. Read SEC document |
| September 02, 2022 Filed Sep 2, 2022 22:29 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $37.89 | $0.00 |
DisclosureSEC source: 0001127602-22-022049 · form4.xml · derivative · entry 7 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 2,500 shares Expires 2032-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2022 Filed Sep 2, 2022 22:29 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 5,834 | $0.00 Strike: $24.32 | $0.00 |
DisclosureSEC source: 0001127602-22-022049 · form4.xml · derivative · entry 6 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,834 shares Expires 2031-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2022 Filed Sep 2, 2022 22:29 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 3,035 | $0.00 Strike: $10.68 | $0.00 |
DisclosureSEC source: 0001127602-22-022049 · form4.xml · derivative · entry 5 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,035 shares Expires 2029-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2022 Filed Sep 2, 2022 22:29 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 11,369 | $53.97 | $613,584.93 |
DisclosureSEC source: 0001127602-22-022049 · form4.xml · nonDerivative · entry 4 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,170 Read SEC document |
| September 02, 2022 Filed Sep 2, 2022 22:29 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,500 | $37.89 | $94,725.00 |
DisclosureSEC source: 0001127602-22-022049 · form4.xml · nonDerivative · entry 3 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2022 Filed Sep 2, 2022 22:29 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 5,834 | $24.32 | $141,882.88 |
DisclosureSEC source: 0001127602-22-022049 · form4.xml · nonDerivative · entry 2 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2022 Filed Sep 2, 2022 22:29 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 3,035 | $10.68 | $32,413.80 |
DisclosureSEC source: 0001127602-22-022049 · form4.xml · nonDerivative · entry 1 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2022 Filed Jul 12, 2022 20:32 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 137 | $41.00 | $5,617.00 |
DisclosureSEC source: 0001127602-22-019239 · form4.xml · nonDerivative · entry 1 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,170 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Share are fully vested from the moment of grant. Shares are issued at per share price of $41.00, representing the closing stock price of the Issuer's common stock on July 1, 2022. Read SEC document |
| May 10, 2022 Filed May 11, 2022 22:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $37.89 | $0.00 |
DisclosureSEC source: 0001061983-22-000121 · edgardoc.xml · derivative · entry 2 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-05-10 F2 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments, the first such installment vesting on 06/10/2022 and the last such installment vesting on 05/10/2023. Read SEC document |
| May 10, 2022 Filed May 11, 2022 22:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-22-000121 · edgardoc.xml · nonDerivative · entry 1 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,033 F1 · kind: Comprised of restricted stock units that will vest in full and in one installment on 05/10/2023. Read SEC document |
| April 01, 2022 Filed Apr 1, 2022 23:17 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 146 | $38.38 | $5,603.48 |
DisclosureSEC source: 0001061983-22-000089 · edgardoc.xml · nonDerivative · entry 1 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,033 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are fully vested from the moment of grant. Shares issued at per share price of $38.38, representing the Issuer's closing stock price on April 1, 2022. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 21:47 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 122 | $46.00 | $5,612.00 |
DisclosureSEC source: 0001061983-22-000012 · edgardoc.xml · nonDerivative · entry 1 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,887 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $46.00, representing the Issuer's closing stock price on January 3, 2022. F2 · balance_after: Amount includes 1,887 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 22:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,166 | $0.00 Strike: $24.32 | $0.00 |
DisclosureSEC source: 0001061983-21-000268 · edgardoc.xml · derivative · entry 9 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,834 Underlying: Common Stock · 4,166 shares Expires 2031-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 22:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $21.61 | $0.00 |
DisclosureSEC source: 0001061983-21-000268 · edgardoc.xml · derivative · entry 8 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2030-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 22:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,124 | $0.00 Strike: $15.43 | $0.00 |
DisclosureSEC source: 0001061983-21-000268 · edgardoc.xml · derivative · entry 7 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,124 shares Expires 2030-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 22:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 4,124 | $45.79 | $188,837.96 |
DisclosureSEC source: 0001061983-21-000268 · edgardoc.xml · nonDerivative · entry 6 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,765 F1 · balance_after: Amount includes 1,765 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 22:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 4,124 | $15.43 | $63,633.32 |
DisclosureSEC source: 0001061983-21-000268 · edgardoc.xml · nonDerivative · entry 5 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,889 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount includes 1,765 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 22:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 20,000 | $45.79 | $915,800.00 |
DisclosureSEC source: 0001061983-21-000268 · edgardoc.xml · nonDerivative · entry 4 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,765 F1 · balance_after: Amount includes 1,765 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 22:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 20,000 | $21.61 | $432,200.00 |
DisclosureSEC source: 0001061983-21-000268 · edgardoc.xml · nonDerivative · entry 3 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount includes 1,765 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 22:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 4,166 | $45.79 | $190,761.14 |
DisclosureSEC source: 0001061983-21-000268 · edgardoc.xml · nonDerivative · entry 2 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,765 F1 · balance_after: Amount includes 1,765 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 22:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 4,166 | $24.32 | $101,317.12 |
DisclosureSEC source: 0001061983-21-000268 · edgardoc.xml · nonDerivative · entry 1 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount includes 1,765 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 23:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $14.25 | $0.00 |
DisclosureSEC source: 0001061983-21-000261 · edgardoc.xml · derivative · entry 9 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2027-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 23:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,032 | $0.00 Strike: $12.40 | $0.00 |
DisclosureSEC source: 0001061983-21-000261 · edgardoc.xml · derivative · entry 8 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,032 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 23:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $9.45 | $0.00 |
DisclosureSEC source: 0001061983-21-000261 · edgardoc.xml · derivative · entry 7 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2028-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 23:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 4,032 | $41.21 | $166,140.17 |
DisclosureSEC source: 0001061983-21-000261 · edgardoc.xml · nonDerivative · entry 6 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,765 F1 · balance_after: Amount includes 1,765 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 23:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 4,032 | $12.40 | $49,996.80 |
DisclosureSEC source: 0001061983-21-000261 · edgardoc.xml · nonDerivative · entry 5 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount includes 1,765 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 23:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 20,000 | $41.21 | $824,108.00 |
DisclosureSEC source: 0001061983-21-000261 · edgardoc.xml · nonDerivative · entry 4 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,765 F1 · balance_after: Amount includes 1,765 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 23:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 20,000 | $14.25 | $285,000.00 |
DisclosureSEC source: 0001061983-21-000261 · edgardoc.xml · nonDerivative · entry 3 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount includes 1,765 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 23:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 5,000 | $41.21 | $206,027.00 |
DisclosureSEC source: 0001061983-21-000261 · edgardoc.xml · nonDerivative · entry 2 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,765 F1 · balance_after: Amount includes 1,765 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 23:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 5,000 | $9.45 | $47,250.00 |
DisclosureSEC source: 0001061983-21-000261 · edgardoc.xml · nonDerivative · entry 1 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount includes 1,765 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 23:03 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 306 | $36.74 | $11,242.44 |
DisclosureSEC source: 0001061983-21-000231 · edgardoc.xml · nonDerivative · entry 1 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,765 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $36.74, representing the Issuer's closing stock price on October 1, 2021. F2 · balance_after: Amount includes 1,765 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 21:14 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $10.68 | $0.00 |
DisclosureSEC source: 0001061983-21-000196 · edgardoc.xml · derivative · entry 9 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,035 Underlying: Common Stock · 5,000 shares Expires 2029-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 10, 2021. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 21:14 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,965 | $0.00 Strike: $10.68 | $0.00 |
DisclosureSEC source: 0001061983-21-000196 · edgardoc.xml · derivative · entry 8 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,035 Underlying: Common Stock · 1,965 shares Expires 2029-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 10, 2021. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 21:14 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $10.68 | $0.00 |
DisclosureSEC source: 0001061983-21-000196 · edgardoc.xml · derivative · entry 7 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires 2029-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 10, 2021. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 21:14 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 5,000 | $28.50 | $142,500.00 |
DisclosureSEC source: 0001061983-21-000196 · edgardoc.xml · nonDerivative · entry 6 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,459 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 10, 2021. F2 · balance_after: Amount includes 1,459 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 21:14 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 5,000 | $10.68 | $53,400.00 |
DisclosureSEC source: 0001061983-21-000196 · edgardoc.xml · nonDerivative · entry 5 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 10, 2021. F2 · balance_after: Amount includes 1,459 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 21:14 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,965 | $29.50 | $57,967.50 |
DisclosureSEC source: 0001061983-21-000196 · edgardoc.xml · nonDerivative · entry 4 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,459 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 10, 2021. F2 · balance_after: Amount includes 1,459 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 21:14 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 1,965 | $10.68 | $20,986.20 |
DisclosureSEC source: 0001061983-21-000196 · edgardoc.xml · nonDerivative · entry 3 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 10, 2021. F2 · balance_after: Amount includes 1,459 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 21:14 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 5,000 | $29.00 | $145,000.00 |
DisclosureSEC source: 0001061983-21-000196 · edgardoc.xml · nonDerivative · entry 2 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,459 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 10, 2021. F2 · balance_after: Amount includes 1,459 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 21:14 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 5,000 | $10.68 | $53,400.00 |
DisclosureSEC source: 0001061983-21-000196 · edgardoc.xml · nonDerivative · entry 1 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 10, 2021. F2 · balance_after: Amount includes 1,459 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 21:32 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 63 | $19.77 | $1,245.51 |
DisclosureSEC source: 0001061983-21-000191 · edgardoc.xml · nonDerivative · entry 1 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,459 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $19.77, representing the Issuer's closing stock price on July 7, 2021. F2 · balance_after: Amount includes 1,459 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:44 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 476 | $20.98 | $9,986.48 |
DisclosureSEC source: 0001061983-21-000171 · edgardoc.xml · nonDerivative · entry 1 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,396 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $20.98, representing the Issuer's closing stock price on July 1, 2021. F2 · balance_after: Amount includes 1,396 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.